Conference Coverage

Cognitive impairment signals subclinical vascular disease


 

AT THE EUROPEAN STROKE CONFERENCE

References

The original trial was supported by an investigator-initiated grant from Bristol-Myers Squibb, USA. Ms. Rostamian had no conflicts.

Pages

Recommended Reading

IHC: IV dihydroergotamine linked to increased thrombosis risk
MDedge Internal Medicine
HRS: A fib plus hemodialysis equals no benefit from warfarin
MDedge Internal Medicine
FDA panel set to review two biologic lipid-lowering drugs for approval
MDedge Internal Medicine
ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
MDedge Internal Medicine
‘Modest’ uptake of novel anticoagulants in real-world practice
MDedge Internal Medicine
Panel backs approval of alirocumab, biologic injectable lipid-lowering drug
MDedge Internal Medicine
FDA panel backs evolocumab for lowering LDL in high-risk patients
MDedge Internal Medicine
Handheld ECG helps spot atrial fibrillation after stroke
MDedge Internal Medicine
VIDEO: EULAR updates cardiovascular-disease risk recommendations
MDedge Internal Medicine
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge Internal Medicine